Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics reported continued momentum in the March 2026 quarter as it advances a diversified pipeline of radiopharmaceutical diagnostics and therapeutics. The company is targeting large oncology markets where current options are limited, positioning its imaging agents and radiotherapeutics to potentially enhance clinical decision-making and patient outcomes.
The company completed enrolment in its U.S. Phase 2b trial of imaging agent RAD 101 in recurrent brain metastases, following interim data showing 90% concordance with MRI and supported by FDA Fast Track Designation, reinforcing confidence in its diagnostic platform. Radiopharm also presented encouraging early Phase 0/1 data for therapeutic candidate RAD 202, received a positive safety committee recommendation to escalate dosing, and initiated two new first-in-human Phase 1 radiotherapy trials—RV-01 in various tumor types and RAD 402 in advanced prostate cancer—highlighting increased platform productivity and upcoming clinical milestones for stakeholders.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals that combine diagnostics and therapeutics for cancers with high unmet medical need. Listed on the ASX and Nasdaq, the company focuses on imaging agents and radiotherapeutic candidates aimed at improving detection and treatment across various solid tumors, including brain metastases and advanced prostate cancer.
Average Trading Volume: 3,506,139
Technical Sentiment Signal: Sell
Current Market Cap: A$74.43M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.